186 related articles for article (PubMed ID: 25860937)
21. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
22. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
[TBL] [Abstract][Full Text] [Related]
23. The potential utility of serum CA 72-4 as a marker for stage IV esophageal adenocarcinoma.
Njei B; Birk J; Vaziri H
Conn Med; 2013 Mar; 77(3):141-5. PubMed ID: 23593659
[TBL] [Abstract][Full Text] [Related]
24. Comparison of serum CA72-4, CEA, TPA, CA19-9 and CA125 levels in gastric cancer patients and correlation with recurrence.
Lai IR; Lee WJ; Huang MT; Lin HH
Hepatogastroenterology; 2002; 49(46):1157-60. PubMed ID: 12143226
[TBL] [Abstract][Full Text] [Related]
25. Serum CA125 is a novel predictive marker for pancreatic cancer metastasis and correlates with the metastasis-associated burden.
Liu L; Xu HX; Wang WQ; Wu CT; Xiang JF; Liu C; Long J; Xu J; Fu de L; Ni QX; Houchen CW; Postier RG; Li M; Yu XJ
Oncotarget; 2016 Feb; 7(5):5943-56. PubMed ID: 26745601
[TBL] [Abstract][Full Text] [Related]
26. Serum CA 19-9 and CEA levels as a prognostic factor in pancreatic adenocarcinoma.
Lee KJ; Yi SW; Chung MJ; Park SW; Song SY; Chung JB; Park JY
Yonsei Med J; 2013 May; 54(3):643-9. PubMed ID: 23549809
[TBL] [Abstract][Full Text] [Related]
27. Leukemia inhibitory factor is a novel biomarker to predict lymph node and distant metastasis in pancreatic cancer.
Jiang W; Bai W; Li J; Liu J; Zhao K; Ren L
Int J Cancer; 2021 Feb; 148(4):1006-1013. PubMed ID: 32914874
[TBL] [Abstract][Full Text] [Related]
28. Intensive risk-adjusted follow-up with the CEA, TPA, CA19.9, and CA72.4 tumor marker panel and abdominal ultrasonography to diagnose operable colorectal cancer recurrences: effect on survival.
Nicolini A; Ferrari P; Duffy MJ; Antonelli A; Rossi G; Metelli MR; Fulceri F; Anselmi L; Conte M; Berti P; Miccoli P
Arch Surg; 2010 Dec; 145(12):1177-83. PubMed ID: 21173292
[TBL] [Abstract][Full Text] [Related]
29. Serum CA 19-9 response to neoadjuvant therapy is associated with outcome in pancreatic adenocarcinoma.
Boone BA; Steve J; Zenati MS; Hogg ME; Singhi AD; Bartlett DL; Zureikat AH; Bahary N; Zeh HJ
Ann Surg Oncol; 2014 Dec; 21(13):4351-8. PubMed ID: 25092157
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Serum Interleukin-17 (IL-17) Levels as a Diagnostic Marker in Pancreatic Adenocarcinoma.
Karabulut S; Afsar ÇU; Karabulut M; Alış H; Kılıc L; Çikot M; Yasasever CT; Aykan NF
J Gastrointest Cancer; 2016 Mar; 47(1):47-54. PubMed ID: 26637231
[TBL] [Abstract][Full Text] [Related]
31. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer.
Aldakkak M; Christians KK; Krepline AN; George B; Ritch PS; Erickson BA; Johnston FM; Evans DB; Tsai S
HPB (Oxford); 2015 Oct; 17(10):942-52. PubMed ID: 26255895
[TBL] [Abstract][Full Text] [Related]
32. Analysis on survival and prognostic factors in patients with resectable pancreatic adenocarcinoma.
Lin R; Han CQ; Wang WJ; Liu J; Qian W; Ding Z; Hou XH
J Huazhong Univ Sci Technolog Med Sci; 2017 Aug; 37(4):612-620. PubMed ID: 28786050
[TBL] [Abstract][Full Text] [Related]
33. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
34. Locally advanced pancreatic cancer: association between prolonged preoperative treatment and lymph-node negativity and overall survival.
Kadera BE; Sunjaya DB; Isacoff WH; Li L; Hines OJ; Tomlinson JS; Dawson DW; Rochefort MM; Donald GW; Clerkin BM; Reber HA; Donahue TR
JAMA Surg; 2014 Feb; 149(2):145-53. PubMed ID: 24306217
[TBL] [Abstract][Full Text] [Related]
35. Significance and prognostic value of increased serum direct bilirubin level for lymph node metastasis in Chinese rectal cancer patients.
Gao C; Fang L; Li JT; Zhao HC
World J Gastroenterol; 2016 Feb; 22(8):2576-84. PubMed ID: 26937145
[TBL] [Abstract][Full Text] [Related]
36. High expression of delta-like ligand 4 predicts poor prognosis after curative resection for pancreatic cancer.
Chen HT; Cai QC; Zheng JM; Man XH; Jiang H; Song B; Jin G; Zhu W; Li ZS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S464-74. PubMed ID: 21822553
[TBL] [Abstract][Full Text] [Related]
37. [Evaluation of CA72-4 as a tumor marker in patients with gastric cancer].
Ubukata H; Katano M; Motohashi G; Kasuga T; Takemura A; Tabuchi T; Tabuchi T
Gan To Kagaku Ryoho; 2003 Oct; 30(11):1821-4. PubMed ID: 14619529
[TBL] [Abstract][Full Text] [Related]
38. Pattern of lymph node involvement and prognosis in pancreatic adenocarcinoma: direct lymph node invasion has similar survival to node-negative disease.
Pai RK; Beck AH; Mitchem J; Linehan DC; Chang DT; Norton JA; Pai RK
Am J Surg Pathol; 2011 Feb; 35(2):228-34. PubMed ID: 21263243
[TBL] [Abstract][Full Text] [Related]
39. [Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].
Soriano-Izquierdo A; Adet AC; Gallego R; Miquel R; Castells A; Pellisé M; Nadal C; López-Boado MA; Piqué JM; Gascón P; Conill C; Bombí A; Fernández-Cruz L; Maurel J; Navarro S
Med Clin (Barc); 2009 Feb; 132(5):163-71. PubMed ID: 19211081
[TBL] [Abstract][Full Text] [Related]
40. Clinical and pathological features of five-year survivors after pancreatectomy for pancreatic adenocarcinoma.
Kimura K; Amano R; Nakata B; Yamazoe S; Hirata K; Murata A; Miura K; Nishio K; Hirakawa T; Ohira M; Hirakawa K
World J Surg Oncol; 2014 Nov; 12():360. PubMed ID: 25429841
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
